Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of FMX103 (minocycline) for the treatment of moderate-to-severe papulopustular rosacea.

Trial Profile

A phase III trial of FMX103 (minocycline) for the treatment of moderate-to-severe papulopustular rosacea.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2018

At a glance

  • Drugs Minocycline (Primary)
  • Indications Rosacea
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2018 According to a Foamix media release, Dr. Linda Stein Gold (dermatologist at Henry Ford Health System), is the principal investigator for this trial.
    • 07 Nov 2018 Results presented in the Foamix media release.
    • 07 Nov 2018 Primary endpoint ( Mean change from baseline in inflammatory lesion counts in each treatment group at week 12) has been met, according to a Foamix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top